These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9811391)

  • 1. Metabolic effects of erythropoietin in patients on peritoneal dialysis.
    Mak RH
    Pediatr Nephrol; 1998 Oct; 12(8):660-5. PubMed ID: 9811391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia.
    Mak RH
    J Pediatr; 1996 Jul; 129(1):97-104. PubMed ID: 8757568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance in uremia: effect of dialysis modality.
    Mak RH
    Pediatr Res; 1996 Aug; 40(2):304-8. PubMed ID: 8827782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia.
    Mak RH
    Am J Physiol; 1996 May; 270(5 Pt 2):F839-44. PubMed ID: 8928846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.
    Gunnell J; Yeun JY; Depner TA; Kaysen GA
    Am J Kidney Dis; 1999 Jan; 33(1):63-72. PubMed ID: 9915269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
    Allegra V; Martimbianco L; Vasile A
    Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
    Charytan C; Goldfarb-Rumyantzev A; Wang YF; Schwenk MH; Spinowitz BS
    Am J Nephrol; 1998; 18(6):498-503. PubMed ID: 9845824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In patients treated with peritoneal dialysis, icodextrin improves erythropoietin-resistant anemia through blockade of asialo receptors on hepatocytes.
    Adachi Y; Nakagawa Y; Nishio A
    Adv Perit Dial; 2006; 22():41-4. PubMed ID: 16983937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte PC-1 activity in patients on maintenance haemodialysis treated with human erythropoietin and 1-alpha-D3.
    Stefanovic V; Djordjevic V; Ivic M; Mitic-Zlatkovic M; Vlahovic P
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):55-60. PubMed ID: 15802034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of erythropoietin therapy on the lipid profile in end-stage renal failure.
    Pollock CA; Wyndham R; Collett PV; Elder G; Field MJ; Kalowski S; Lawrence JR; Waugh DA; George CR
    Kidney Int; 1994 Mar; 45(3):897-902. PubMed ID: 8196294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia.
    Mak RH
    Kidney Int; 1998 May; 53(5):1353-7. PubMed ID: 9573552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
    Tarng DC; Huang TP; Doong TI
    Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of erythropoietin on glucose tolerance in hemodialysis patients.
    Chagnac A; Weinstein T; Zevin D; Korzets A; Hirsh J; Gafter U; Levi J
    Clin Nephrol; 1994 Dec; 42(6):398-400. PubMed ID: 7882604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P; Andre JL; Treize G; Leroy B
    Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis.
    Wei M; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2007; 39(3):935-40. PubMed ID: 17534732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients.
    Beusterien KM; Nissenson AR; Port FK; Kelly M; Steinwald B; Ware JE
    J Am Soc Nephrol; 1996 May; 7(5):763-73. PubMed ID: 8738812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
    Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
    Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.